According to The Financial Express, fundamentally strong stocks trading close to their 52-week highs can indicate a combination of improving earnings, strong business prospects and sustained investor confidence. The selection criteria focused on companies with strong profitability track record, ROCE and ROE of at least 25%, and stocks close to 52-week highs. Investors should examine earnings growth, return ratios, debt levels, cash flows, valuations, and future growth prospects before investing. As per Zacks Investment Research, the best momentum stocks are identified through a screen that narrows down Zacks Rank #1 (Strong Buy) stocks with upward price momentum trading within 20% of their 52-week highs, using PEG ratio and Price to Sales ratio to ensure value.
As reported by The Financial Express, Oracle Financial Services Software trades at ₹12,117 as of 6 September 2026, just under 3% below its 52-week high of ₹12,540. The Indian software company focused on global banking and financial services has demonstrated strong financial performance with ROCE of 48.1% and ROE of 34.5%. The company reported revenues of ₹31,252 million vs ₹18,522 million YoY, with net profit surging to ₹14,155 million vs ₹6,419 million YoY. According to the FY26 annual report, Oracle has significantly expanded its cloud services portfolio for banking with multiple new services including retail lending, collections, cash management, and trade finance cloud services.
According to The Financial Express, Solar Industries India Limited trades at ₹21,458 as of 6 September 2026, close to its high of ₹21,640. The company, a leading manufacturer of industrial explosives and defence products, reported revenues of ₹36,682 million vs ₹21,545 million YoY and net profit of ₹6,576 million vs ₹3,526 million YoY. The company maintains a strong order book of ₹213.5 billion, providing revenue visibility for the next few years. Solar Industries serves mining, infrastructure, and construction sectors while defence has become an increasingly important growth driver.
As reported by The Financial Express, Titan Company trades near ₹5,000 against its 52-week high of ₹5,187, with an impressive ROCE of 51% and ROE of 31.6%. The Tata Group company reported net sales of ₹875,840 million in FY26 compared to ₹604,560 million in FY25. Q1FY27 was particularly strong with Consumer Businesses registering 40% YoY growth due to innovation-led differentiation across jewelry, watches, eyecare, and emerging businesses. The company operates multiple brands including Tanishq, CaratLane, Mia, Zoya, Titan Eye+, SKINN, and Taneira across jewelry, watches, eyewear, fragrances, and ethnic wear segments.
According to Zacks Investment Research, Merck currently trades at ₹19.85 forward earnings, higher than the industry average of 18.70. The stock is trading above its 5-year mean of 12.90, indicating premium valuation. However, earnings estimates have declined from $4.31 per share for 2026 to $2.97 per share and from $9.85 per share for 2027 to $9.66 per share over the past 60 days. Merck's flagship drug Keytruda accounts for more than 55% of pharmaceutical sales and is approved for 44 indications spanning 19 tumor types. The company expects more than $70 billion of potential non-risk-adjusted commercial opportunity for its current pipeline by mid-2030s, significantly exceeding the peak consensus sales estimate of $35 billion for Keytruda in 2028.
